Plasma Rich in Growth Factors for the Treatment of Ocular Surface Diseases

ABSTRACT

Purpose: The purpose of this work is to describe and review the technology of plasma rich in growth factors (PRGF), a novel blood derivative product, in the treatment of ocular surface disorders.

Methods: To demonstrate the importance of this technology in the treatment of ocular pathologies, a thorough review of the preclinical and clinical literature results obtained following use of the different therapeutic formulations of PRGF was carried out. A literature search for applications of PGRF plasma in the ophthalmology field was carried out using the PubMed database.

Results: PRGF involves the use of patient’s own biologically active proteins, growth factors, and biomaterial scaffolds for therapeutic purposes. This procedural technology is gaining interest in regenerative medicine due to its potential to stimulate and accelerate the tissue healing processes. The versatility and biocompatibility of this technology opens the door to a personalized medicine on ocular tissue regeneration. This review discusses the state of the art of the new treatments and technologies developed to promote ocular surface tissue regeneration. The standardized protocol that has been developed to source eye drops from PRGF technology is also described. The preclinical research, together with the most relevant clinical applications are summarized and discussed.

Conclusions: The preliminary results suggest that the use of PRGF to enhance ocular tissue regeneration is safe and efficient.

KEYWORDS:

• Cornea
• ocular surface
• platelet-rich plasma
• PRGF
• PRP

Declaration of interest

E.A. is the Scientific Director of, and GO, FM, and MF are scientists at BTI Biotechnology Institute, a dental implant company conducting research in the fields of oral implantology and PRGF-Endoret technology.